Last updated: May 29, 2026

Lathrop Gpm LLP

95 pending office actions • 77 clients • 88 examiners • 57 art units • 0 of 95 (0%) have an AI response strategy ready • 161 patents granted in the last 365 days

Portfolio Summary

Total Pending OAs

Non-Final OAs

Final Rejections

Advisory / Quayle

Response Deadline Pressure

Based on the USPTO statutory response window for each pending office action. 94 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.

Overdue

Due this week

Due this month

Due in next 60 days

Due later

Deadline Fire Line

Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 94 of the docket's apps have a known mailing date.

Overdue (51)Due ≤ 7 days (5)Due ≤ 30 days (24)Due ≤ 60 days (8)Due later (6)

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

Hard (2%)

Medium (59%)

Easy (13%)

Unknown (26%)

Rejection Statute Mix

Bucket	Cases
§101 only	2 (2%)
§103 only	48 (51%)
§102 only	5 (5%)
§112 only	12 (13%)
Double-patenting + other	3 (3%)
No statute on record	25 (26%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

Life Sciences

82% of docket

Information Tech

1% of docket

Communications

3% of docket

Semiconductors

3% of docket

Mechanical / Eng

11% of docket

Business / Other

0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

950 h

Manual time on pending OAs

190 h

Time saved (low, 20%)

332 h

Time saved (mid, 35%)

8.3 wks

FTE-weeks freed (mid)

Top Examiners on this docket

Examiner	Apps on this docket	Allow rate	Interview lift
VYAS, KEYUR ANILKUMAR	3	51.5%	+63.5%
LYLE, SOPHIA YUAN	3	57.4%	+56.8%
GROOMS, TIFFANY NICOLE	2	58.8%	+45.3%
GAMBLE JR, RANDALL LEE	2	48.3%	+24.7%
THOMAS, TIMOTHY P	2	26.2%	+38.3%
ESPINOSA, CLAUDIA EDILMA	1	53.2%	+58.5%
PHAN, DOAN THI-THUC	1	42.7%	+49.8%
HUANG, GIGI GEORGIANA	1	31.8%	+30.4%
FILIPCZYK, MARCIN R	1	64.6%	+37.2%
AMICK, JACOB M	1	78.5%	+0.1%

Hard Cases (4)

Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 4 ordered by deadline are shown.

App #	Title	Examiner	Due in
17050462	RADIATION SENSITIVITY ENHANCING COMPOSITION CONTAINING ARIPIPRAZOLE AS ACTIVE INGREDIENT	THOMAS, TIMOTHY P	99d overdue
17937778	RADIATION SENSITIVITY ENHANCING COMOPOSITION CONTAINING ARIPIPRAZOLE AS ACTIVE INGREDIENT	THOMAS, TIMOTHY P	72d overdue
17909036	METHOD FOR QUANTIFYING ADIPONECTIN AND ANALYTICAL REAGENT USED THEREOF	BORGEEST, CHRISTINA M	20d
18299344	ARTIFICIAL INTELLIGENCE HEALTH DIAGNOSTIC SYSTEM AND METHOD	AKOGYERAM II, NICHOLAS A	70d

Interview Candidates (16)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.

App #	Title	Examiner	Due in
17391475	OLIGONUCLEOTIDES FOR HTT-1A MODULATION	VYAS, KEYUR ANILKUMAR	258d overdue
17050462	RADIATION SENSITIVITY ENHANCING COMPOSITION CONTAINING ARIPIPRAZOLE AS ACTIVE INGREDIENT	THOMAS, TIMOTHY P	99d overdue
17937778	RADIATION SENSITIVITY ENHANCING COMOPOSITION CONTAINING ARIPIPRAZOLE AS ACTIVE INGREDIENT	THOMAS, TIMOTHY P	72d overdue
17313369	Biological Fluid Filtration System	LYLE, SOPHIA YUAN	67d overdue
17796953	METHOD FOR FUNCTIONALISING A CELLULOSE SUPPORT WITH METAL NANOPARTICLES AND ELECTROANALYTICAL SENSOR COMPRISING THE FUNCTIONALISED CELLULOSE SUPPORT	GAMBLE JR, RANDALL LEE	46d overdue
17162450	Biological Fluid Filtration System	LYLE, SOPHIA YUAN	35d overdue
17313421	Biological Fluid Filtration System	LYLE, SOPHIA YUAN	30d overdue
19174814	ARTIFICIAL INTELLIGENCE POWERED CHIEF OF STAFF BOT	FILIPCZYK, MARCIN R	23d overdue

Client Portfolio (77 clients)

Client (Assignee)	Pending OAs
Astrin Biosciences	4
UNIVERSITY OF MASSACHUSETTS	4
DH TECHNOLOGIES DEVELOPMENT PTE. LTD.	3
scPharmaceuticals Inc.	2
WAABI Innovation Inc.	2
INTABIO, LLC	2
BIONTECH SE	2
MENDUS B.V.	2
On Target Laboratories, LLC	2
MIT	2
NATIONAL UNIVERSITY CORPORATION SHIGA UNIVERSITY OF MEDICAL SCIENCE	2
KOREA INSTITUTE OF RADIOLOGICAL & MEDICAL SCIENCES	2
SPHERITECH LTD	2
FILAMON LTD	1
GLOBAL LIFE SCIENCES SOLUTIONS UK LIMITED	1
TransforML Platforms Inc.	1
EKU POWER DRIVES INC.	1
COLUMBIA INSURANCE COMPANY	1
Flanders Electric	1
K-Orbital LLC	1
Arthrex	1
Zhejiang Beihuan	1
THE AKKERMANSIA COMPANY	1
IKARIA INC.	1
Animal Control Technologies (Australia) Pty Ltd.	1
KINASET THERAPEUTICS, INC.	1
BEDIMENSIONAL S.P.A.	1
PONSSE OYJ	1
IDEAYA BIOSCIENCES, INC.	1
Mass Luminosity, Inc.	1
Pfizer	1
KYMAB LIMITED	1
Kyushu University	1
Macrobiome Therapeutics Pty Ltd.	1
UNIVERSITY OF TSUKUBA	1
4D VISION CORP	1
Ausmed Global	1
Incyte	1
Rege Nephro Co., Ltd.	1
The New Zealand Institute for Plant and Food Research Limited	1
UNIL	1
Infinite Roots	1
Roche	1
Merck & Co.	1
THE UNIVERSITY OF TOKYO	1
CARDIOVASCULAR LAB S.R.L.	1
University of Illinois	1
ALS THERAPY DEVELOPMENT INSTITUTE	1
UNIVERSITY OF SYDNEY	1
Evan Greebel	1
SERVIER PHARMACEUTICALS LLC	1
UNIVERSITA' DEGLI STUDI DEL PIEMONTE ORIENTALE "A. AVOGADRO"	1
KANTONSSPITAL ST. GALLEN	1
Alkermes	1
Dragonfly Therapeutics	1
Mimetas	1
GREY WOLF THERAPEUTICS LIMITED	1
ENDER HOLDING AG	1
University of Zurich	1
PATHIOS THERAPEUTICS LIMITED	1
i2O Therapeutics	1
NIPPON CHEMIPHAR CO., LTD.	1
Tatsuya SAWAMURA	1
PURDUE RESEARCH FOUNDATION	1
Freshpoint Quality Assurance	1
Weizmann Institute of Science	1
ALMAC DISCOVERY LIMITED	1
Cardiovascular Lab S.p.A.	1
GE HEALTHCARE AS	1
CULLINAN THERAPEUTICS, INC.	1
VICO Therapeutics B.V.	1
NIDO BIOSCIENCES, INC.	1
Warrant Pharmaceutical	1
Scuola Internazionale Superiore Studi Internazionale Superiore Di Studi Avanzati - SISSA	1
Genesis Pharma SA	1
University of California	1
NORIA THERAPEUTICS, INC.	1

Show all 77 rows (27 more)

Top Art Units

Art Unit	Apps
1637	5
1654	4
1625	4
1618	4
1613	3
1647	3
1796	3
3747	2
1658	2
1621	2

Pending Office Actions

App #	Title	Client	Examiner	Art Unit	Statutes	Status	Due in	AI	Filed
19355164	EPIDERMAL GROWTH FACTOR RECEPTOR INHIBITORS	Filamon Ltd.	ESPINOSA, CLAUDIA EDILMA	1654	§103	Non-Final OA	22d	Pending	Oct 10, 2025
19337639	METHOD FOR PRODUCING A LIQUID COMPOSITION INCLUDING A NANOPARTICLE, AND FORMULATION THEREOF	Global Life Sciences Solutions UK Limited	PHAN, DOAN THI-THUC	1613	§103	Final Rejection	84d	Pending	Sep 23, 2025
19271284	PHARMACEUTICAL FORMULATIONS FOR SUBCUTANEOUS ADMINISTRATION OF FUROSEMIDE	Scpharmaceuticals Inc.	HUANG, GIGI GEORGIANA	1613	Other	Non-Final OA	7d	Pending	Jul 16, 2025
19174814	ARTIFICIAL INTELLIGENCE POWERED CHIEF OF STAFF BOT	TransforML Platforms Inc.	FILIPCZYK, MARCIN R	2153	§102	Non-Final OA	23d overdue	Pending	Apr 09, 2025
19011787	TRANSMISSION SHAFT BRAKE FOR ENGINE AUTO RESTART	Eku Power Drives Inc.	AMICK, JACOB M	3747	§112	Non-Final OA	6d	Pending	Jan 07, 2025
18835285	AUTONOMOUS SYSTEM TRAINING AND TESTING	Waabi Innovation Inc.	TSWEI, YU-JANG	2614	§103	Non-Final OA	9d	Pending	Aug 01, 2024
18780957	HIDDEN EDGE FOR FLOORING FINISHING	Columbia Insurance Company	MAESTRI, PATRICK J	3635	§103	Non-Final OA	28d	Pending	Jul 23, 2024
18655104	NATURAL GAS ENGINE START AND LOAD SYSTEM	Flanders Electric Motor Service, LLC	LIETHEN, KURT PHILIP	3747	§103	Final Rejection	21d	Pending	May 03, 2024
18649142	REACTIONS USING FACILITATORS AND MODERATORS	K-Orbital LLC	GARNER, LILY CRABTREE	3646	§103	Non-Final OA	37d overdue	Pending	Apr 29, 2024
18698595	Wound Management Systems	Arthrex, Inc.	STEPHENS, JACQUELINE F	3781	§103	Non-Final OA	12d	Pending	Apr 04, 2024
18598279	ANTI-PINCH FOLDABLE TROLLEY	Zhejiang Beihuan Outdoor Products Co., Ltd.	OLSZEWSKI, JOHN	3617	§103	Non-Final OA	17d overdue	Pending	Mar 07, 2024
18684682	COMPOSITION COMPRISING PASTEURIZED AKKERMANSIA FOR THE TREATMENT OR PREVENTION OF IBS-RELATED ANXIETY	The Akkermansia Company	MOREAU, NASHARA LOUISE	1655	§103	Non-Final OA	8d overdue	Pending	Feb 18, 2024
18439838	FUNTIONALLY MODIFIED POLYPEPTIDES AND RADIOBIOSYNTHESIS	Ikaria Inc.	STEELE, AMBER D	1658	Other	Non-Final OA	9d overdue	Pending	Feb 13, 2024
18683343	DISCRETE PEG MOLECULES AS ANALYTES FOR MS CALIBRATION AND TUNING IN POSITIVE AND NEGATIVE MODES	DH TECHNOLOGIES DEVELOPMENT PTE. LTD.	GUTIERREZ, GISSELLE M	2884	§102	Non-Final OA	86d overdue	Pending	Feb 13, 2024
18572622	IRRADIATION OF GRAIN OR SEEDS	Animal Control Technologies (Australia) Pty Ltd.	BECKER, DREW E	1792	§102	Non-Final OA	56d	Pending	Dec 20, 2023
18526352	FORMULATION OF A PAN-JAK INHIBITOR	Kinaset Therapeutics, Inc.	STEVENS, MARK V	1613	§103	Non-Final OA	3d overdue	Pending	Dec 01, 2023
18561645	COATING SYSTEM FOR PROTECTING A SUBSTRATE	BEDIMENSIONAL S.P.A.	AHMED, SHEEBA	1787	§103	Final Rejection	34d	Pending	Nov 16, 2023
18558764	DAMPING SYSTEM FOR A CABIN OF A MOVABLE WORK MACHINE	Ponsse Oyj	BEMKO, TARAS P	3672	§103	Final Rejection	—	Pending	Nov 03, 2023
18501729	COMBINATION THERAPY COMPRISING A MAT2A INHIBITOR AND A TYPE II PRMT INHIBITOR	Ideaya Biosciences, Inc.	HUTTER, GILLIAN A	1625	Other	Non-Final OA	8d overdue	Pending	Nov 03, 2023
18492635	PROBABILISTIC MULTI-PARTY AUDIO TRANSLATION	Mass Luminosity, Inc.	MEIS, JON CHRISTOPHER	2654	§103	Final Rejection	27d	Pending	Oct 23, 2023
18555058	COMBINATION THERAPY COMPRISING A PKC INHIBITOR AND A MEK INHIBITOR	Pfizer, Inc.	O DELL, DAVID K	1621	§103	Non-Final OA	5d	Pending	Oct 12, 2023
18284952	THERAPEUTIC INHIBITORS OF GDF15 SIGNALLING	Kymab Limited	LEE, YIE CHIA	1642	§112	Non-Final OA	23d overdue	Pending	Sep 29, 2023
18553271	METHODS OF TREATMENT USING FUROSEMIDE	Scpharmaceuticals Inc.	SHIM, DAVID M.	1626	§103	Non-Final OA	19d	Pending	Sep 29, 2023
18284129	METHOD FOR PRODUCING OVARIAN SOMATIC CELL-LIKE CELLS, AND METHOD FOR INDUCING DIFFERENTIATION OF PRIMATE PLURIPOTENT STEM CELLS INTO OVARIAN SOMATIC CELL-LIKE CELLS	Kyushu University, National University Corporation	ROGERS, ERIC JASON	1638	§112	Non-Final OA	15d	Pending	Sep 26, 2023
18550807	PROTEINS AND USES THEREOF	Macrobiome Therapeutics Pty Ltd.	BROWN, DALIYAH MONYHE	1654	§103	Non-Final OA	33d	Pending	Sep 15, 2023
18548708	CAPILLARY ELECTROPHORESIS METHODS FOR QUANTIFYING VIRAL SPECIES	DH TECHNOLOGIES DEVELOPMENT PTE. LTD.	SIFFORD, JEFFREY MARK	1671	§103	Non-Final OA	77d	Pending	Sep 01, 2023
18448283	SOFTWARE FOR MICROFLUIDIC SYSTEMS INTERFACING WITH MASS SPECTROMETRY	Intabio, LLC	NGHIEM, MICHAEL P	2857	§112	Non-Final OA	18d overdue	Pending	Aug 11, 2023
18276762	BODY TEMPERATURE LOWERING AGENT, BODY TEMPERATURE ELEVATION SUPPRESSOR, FOOD COMPOSITION FOR LOWERING BODY TEMPERATURE,AND FOOD COMPOSITION FOR SUPPRESSING BODY TEMPERATURE ELEVATION	UNIVERSITY OF TSUKUBA	ROZOF, TIMOTHY R	1625	§112	Non-Final OA	56d	Pending	Aug 10, 2023
18361156	MODULAR MULTI-PANEL SOLAR CELL	4D Vision Corp.	CANNON, RYAN SMITH	1726	§103	Final Rejection	114d overdue	Pending	Jul 28, 2023
18040321	TESTING DEVICE WITH BUILT-IN LIQUID STORAGE	AusMed Global Limited	MUI, CHRISTINE T	1797	§102	Non-Final OA	29d	Pending	Jul 14, 2023
18349606	FUSED TRICYCLIC COMPOUNDS AS INHIBITORS OF KRAS G12V MUTANTS	Incyte Corporation	DEKARSKE, MADELINE MCGUIRE	1622	Other	Non-Final OA	46d	Pending	Jul 10, 2023
18271112	MEDIUM FOR CULTURING AND EXPANDING NEPHRON PROGENITOR CELLS, METHOD FOR CULTURING AND EXPANDING NEPHRON PROGENITOR CELLS, AND METHOD FOR PRODUCING RENAL ORGANOIDS	Rege Nephro Co., Ltd.	O'NEILL, MARISOL ANN	1633	§103	Non-Final OA	21d	Pending	Jul 06, 2023
18341210	BOYSENBERRY COMPOSITIONS AND METHODS OF PREPARATION AND USE THEREOF	The New Zealand Institute for Plant and Food Research Limited	VISONE, THOMAS J	1672	DPOther	Non-Final OA	70d	Pending	Jun 26, 2023
18209609	THREE DIMENSIONAL OBJECT RECONSTRUCTION FOR SENSOR SIMULATION	Waabi Innovation Inc.	BADER, ROBERT N.	2611	§103	Final Rejection	56d	Pending	Jun 14, 2023
18267288	ANTI-APRIL ANTIBODIES AND USES THEREOF	Université De Lausanne	GURLEY, JAMI MICHELLE	1647	§112	Non-Final OA	3d overdue	Pending	Jun 14, 2023
18255420	PRODUCTION OF FUNGAL BIOMASS	Mushlabs GmbH	ARIANI, KADE	1651	§103	Non-Final OA	17d overdue	Pending	Jun 01, 2023
18254625	SYSTEM AND METHODS FOR SEGMENTED FLOW ANALYSIS	DH TECHNOLOGIES DEVELOPMENT PTE. LTD.	MASKELL, MICHAEL P	2878	§102	Non-Final OA	12d	Pending	May 26, 2023
18038818	ANTIBODY AND TAXANE COMBINATION THERAPY	BIONTECH SE	JUEDES, AMY E	1644	DPOther	Final Rejection	75d	Pending	May 25, 2023
18201626	USE OF ANTI-IL-27 ANTIBODIES	F. Hoffmann-La Roche AG	JOHNSON, TIRONE DEREK	1675	§103	Non-Final OA	45d overdue	Pending	May 24, 2023
18201620	USE OF ANTI-IL-27 ANTIBODIES	Msd International GmbH	FAUST, AMBER KATHLEEN	1643	Other	Non-Final OA	100d overdue	Pending	May 24, 2023
18322675	SYSTEMS, METHODS, AND COMPOSITIONS FOR RNA-GUIDED RNA-TARGETING CRISPR EFFECTORS	The University of Tokyo	GROOMS, TIFFANY NICOLE	1637	§103	Non-Final OA	42d	Pending	May 24, 2023
18197670	USE OF LEUKEMIA-DERIVED CELLS FOR ENHANCING NATURAL KILLER (NK) CELL THERAPY	Mendus B.V.	LARA, CAROLINE MONSERRAT	1633	§103	Non-Final OA	92d overdue	Pending	May 15, 2023
18252896	METHOD FOR DETECTING AND/OR QUANTIFYING A METAL ELEMENT IN A BIOLOGICAL LIQUID	Cardiovascular Lab S.r.l.	GAMBLE JR, RANDALL LEE	1795	§103	Non-Final OA	14d	Pending	May 15, 2023
18252904	NEAR INFRARED-II PROBES AS HIGH AFFINITY TARGETING IMAGING AGENTS AND USES THEREOF	On Target Laboratories, LLC	AEDER, SEAN E	1642	§103	Non-Final OA	1d overdue	Pending	May 15, 2023
18251505	SPLIT PRIME EDITING PLATFORMS	The Board Of Trustees Of The University Of Illinois	HUTSON, RICHARD G	1652	§112	Non-Final OA	127d overdue	Pending	May 02, 2023
18303533	SITE SPECIFIC GENETIC ENGINEERING UTILIZING TRANS-TEMPLATE RNAS	Massachusetts Institute Of Technology	GROOMS, TIFFANY NICOLE	1637	Other	Non-Final OA	3d overdue	Pending	Apr 19, 2023
18303346	COPPER COMPLEXES FOR TREATMENT OF NEURODEGENERATIVE DISORDERS	Als Therapy Development Institute	SABILA, MERCY HELLEN	1654	Other	Final Rejection	60d overdue	Pending	Apr 19, 2023
18299304	THERAPEUTIC RADIOLABELLED CONJUGATES AND THEIR USE IN THERAPY	University Of Sydney	CRAIG, KAILA ANGELIQUE	1618	Other	Non-Final OA	23d overdue	Pending	Apr 12, 2023
18299344	ARTIFICIAL INTELLIGENCE HEALTH DIAGNOSTIC SYSTEM AND METHOD	Evan Greebel	AKOGYERAM II, NICHOLAS A	3686	§101	Final Rejection	70d	Pending	Apr 12, 2023
18193958	METHODS OF TREATING ENHANCING BRAIN TUMORS USING COMBINATION THERAPY	Servier Pharmaceuticals Llc.	TRAN HO, LAM THUY VI	1647	Other	Non-Final OA	23d overdue	Pending	Mar 31, 2023
18029725	SIRT1 INHIBITOR OR ANTAGONIST FOR USE IN PREVENTING AND/OR TREATING AN HPV INDUCED TUMOUR	UNIVERSITA' DEGLI STUDI DEL PIEMONTE ORIENTALE "A. AVOGADRO"	GIBBS, TERRA C	1635	§103	Final Rejection	3d overdue	Pending	Mar 31, 2023
18028702	ANTIBODIES OR ANTIGEN-BINDING FRAGMENTS SPECIFICALLY BINDING TO GREMLIN-1 AND USES THEREOF	Kantonsspital St. Gallen	HADDAD, MAHER M	1641	Other	Non-Final OA	19d	Pending	Mar 27, 2023
18027306	METHOD FOR PREPARING EFFECTOR CELLS WITH DESIRED SPECIFICITY	National University Corporation Shiga University Of Medical Science	ZHU, JIANJIAN	1631	Other	Non-Final OA	2d overdue	Pending	Mar 20, 2023
18183257	Pharmaceutical Compositions Comprising Sorbitan Esters	Alkermes Pharma Ireland Limited	ALLEY, GENEVIEVE S	1617	Other	Final Rejection	28d	Pending	Mar 14, 2023
18119487	MODIFIED CELLS OF LEUKEMIC ORIGIN AND A PD-L1 ANTIBODY FOR ENHANCING THE EFFICACY OF CANCER CELL THERAPY	Mendus B.V.	BUTTICE, AUDREY L	1647	§103	Non-Final OA	131d overdue	Pending	Mar 09, 2023
18041918	TRANSFORMABLE PNEUMATIC SOFT STRUCTURES	Massachusetts Institute Of Technology	LEDERER, SARAH B	3785	§103	Non-Final OA	30d	Pending	Feb 16, 2023
18108961	PROTEINS BINDING NKG2D, CD16 AND NECTIN4	Dragonfly Therapeutics, Inc.	BRISTOL, LYNN ANNE	1643	§103	Final Rejection	1d overdue	Pending	Feb 13, 2023
18004671	MICROFLUIDIC CELL CULTURE DEVICE	Mimetas B.V.	GERHARD, ALISON CLAIRE	1797	§103	Non-Final OA	8d	Pending	Jan 07, 2023
18004386	COMPOUNDS AS MODULATORS OF ENDOPLASMIC RETICULUM AMINOPEPTIDASE 1 (ERAP1)	Grey Wolf Therapeutics Limited	BARSKY, JARED	1628	§112	Final Rejection	5d	Pending	Jan 05, 2023
18091651	DEVICES AND METHODS FOR SAMPLE CHARACTERIZATION	Intabio, LLC	CHIU, TAK LIANG	1777	§112	Non-Final OA	23d overdue	Pending	Dec 30, 2022
18009498	ISOTHERMAL REAL-TIME PCR METHOD FOR DETERMINING PRESENCE OF A PRE-DETERMINED NUCLEIC ACID SEQUENCE IN ANIMAL SAMPLES	Ender Holding AG	HOPPE, EMMA RUTH	1683	Other	Non-Final OA	8d overdue	Pending	Dec 09, 2022
18062311	CENTRIFUGE APHERETIC SYSTEM	Astrin Biosciences, Inc.	KASS, BENJAMIN JOSEPH	1798	§103	Non-Final OA	35d overdue	Pending	Dec 06, 2022
17926757	NOVEL TRANSDUCTION ENHANCERS AND USES THEREOF	UNIVERSITAET ZUERICH	THUESON, HANNA MARIE	1638	§103	Final Rejection	32d overdue	Pending	Nov 21, 2022
17999001	N-(PHENYLAMINOCARBONYL) TETRAHYDRO-ISOQUINOLINES AND RELATED COMPOUNDS AS MODULATORS OF GPR65	Pathios Therapeutics Limited	BAUER, NICOLA MARIA	1621	Other	Non-Final OA	36d overdue	Pending	Nov 16, 2022
17996126	LONG ACTING GLUCAGON RECEPTOR SELECTIVE PEPTIDES AND METHODS OF USE	I2O Therapeutics, Inc.	KONOPELSKI SNAVEL, SARA ELIZABETH	1658	Other	Non-Final OA	49d overdue	Pending	Oct 13, 2022
17937778	RADIATION SENSITIVITY ENHANCING COMOPOSITION CONTAINING ARIPIPRAZOLE AS ACTIVE INGREDIENT	Korea Institute Of Radiological & Medical Sciences	THOMAS, TIMOTHY P	1614	Other	Non-Final OA	72d overdue	Pending	Oct 03, 2022
17915361	MEDICAMENT FOR PREVENTING OR TREATING IRRITABLE BOWEL SYNDROME OR INFLAMMATORY BOWEL DISEASE	Nippon Chemiphar Co., Ltd.	KOSAR, ANDREW D	1625	§112	Non-Final OA	67d overdue	Pending	Sep 28, 2022
17909036	METHOD FOR QUANTIFYING ADIPONECTIN AND ANALYTICAL REAGENT USED THEREOF	Tatsuya Sawamura	BORGEEST, CHRISTINA M	1675	§101	Final Rejection	20d	Pending	Sep 02, 2022
17884998	SYNTHESIS AND COMPOSITION OF AMINO ACID LINKING GROUPS CONJUGATED TO COMPOUNDS USED FOR THE TARGETED IMAGING OF TUMORS	Purdue Research Foundation	PERREIRA, MELISSA JEAN	1618	DPOther	Non-Final OA	62d	Pending	Aug 10, 2022
17760413	METHOD, SYSTEM AND COMPUTER PROGRAM PRODUCTS FOR MANAGEMENT OF SUPPLY CHAINS AND/OR INVENTORY FOR PERISHABLE GOODS	Freshpoint Quality Assurance Ltd.	DELIGI, VANESSA LIMA	3627	§103	Non-Final OA	99d overdue	Pending	Aug 09, 2022
17798415	CHONDROITINASE ABC MUTANTS AND METHODS OF MANUFACTURE AND USE THEREOF	Yeda Research And Development Co. Ltd.	RAGHU, GANAPATHIRAM	1652	§103	Final Rejection	96d overdue	Pending	Aug 09, 2022
17760329	USP7 INHIBITOR FOR USE IN THE TREATMENT OF CANCER	Almac Discovery Limited	REILLY, SOPHIA JANE	1627	§103	Non-Final OA	22d	Pending	Aug 08, 2022
17796953	METHOD FOR FUNCTIONALISING A CELLULOSE SUPPORT WITH METAL NANOPARTICLES AND ELECTROANALYTICAL SENSOR COMPRISING THE FUNCTIONALISED CELLULOSE SUPPORT	Cardiovascular Lab S.p.A.	GAMBLE JR, RANDALL LEE	1795	§103	Non-Final OA	46d overdue	Pending	Aug 02, 2022
17787545	NOVEL MANUFACTURING PROCESS FOR GADOLINIUM COMPLEXES	GE Healthcare AS	ROGERS, JAMES WILLIAM	1618	§103	Non-Final OA	23d	Pending	Jun 20, 2022
17785011	ANTI-SERUM ALBUMIN ANTIBODIES	Cullinan Therapeutics, Inc.	ALLEN, MICHAEL D	1671	§112	Final Rejection	105d overdue	Pending	Jun 13, 2022
17728336	RNA MODULATING OLIGONUCLEOTIDES WITH IMPROVED CHARACTERISTICS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS	VICO Therapeutics B.V.	CHONG, KIMBERLY	1636	Other	Final Rejection	22d	Pending	Apr 25, 2022
17704915	OLIGONUCLEOTIDES FOR SYNGR-3 MODULATION	UNIVERSITY OF MASSACHUSETTS	VYAS, KEYUR ANILKUMAR	1637	§103	Non-Final OA	9d	Pending	Mar 25, 2022
17701888	BICYCLIC COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS	Nido Biosciences, Inc.	MOU, LIYUAN	1628	§103	Non-Final OA	79d overdue	Pending	Mar 23, 2022
17636476	APPLICATION OF FLUORO-SUBSTITUTED 2-AMINOTHIAZOLE-5-AROMATIC CARBOXAMIDE	Hunan Warrant Pharmaceutical Technology Development Co., Ltd.	ISMAIL, REHANA	1625	§103	Non-Final OA	29d	Pending	Feb 18, 2022
17625433	FUNCTIONAL NUCLEIC ACID MOLECULES UPREGULATING THE TRANSLATION OF A FRATAXIN MRNA	Scuola Internazionale Superiore Studi Internazionale Superiore Di Studi Avanzati - Sissa	RAVINDRA, KRISHNA NUGGEHALLI	1636	Other	Non-Final OA	146d overdue	Pending	Jan 07, 2022
17624690	COMBINATION	Genesis Pharma SA	D' AMBROSIO, THEA	1654	Other	Non-Final OA	55d	Pending	Jan 04, 2022
17619837	STABLE COLLOIDAL DRUG AGGREGATES AND METHODS OF MANUFACTURE AND USE THEREOF	The Regents of the University of California	OLSEN, KAELEIGH ELIZABETH	1619	§103	Final Rejection	26d overdue	Pending	Dec 16, 2021
17532636	OLIGONUCLEOTIDES FOR DGAT2 MODULATION	UNIVERSITY OF MASSACHUSETTS	ARIETI, RUTH SOPHIA	1635	Other	Final Rejection	2d overdue	Pending	Nov 22, 2021
17262400	METHOD FOR PRODUCING FOREIGN ANTIGEN RECEPTOR GENE-INTRODUCED CELL	National University Corporation Shiga University Of Medical Science	MIANO, JOSEPH PAUL	1631	Other	Non-Final OA	87d overdue	Pending	Aug 27, 2021
17391475	OLIGONUCLEOTIDES FOR HTT-1A MODULATION	UNIVERSITY OF MASSACHUSETTS	VYAS, KEYUR ANILKUMAR	1637	§103	Non-Final OA	258d overdue	Pending	Aug 02, 2021
17293671	THIOAMIDE-CONTAINING COMPOSITIONS AND METHODS OF USE THEREOF	Noria Therapeutics, Inc.	ELENISTE, PIERRE PAUL	1622	§103	Non-Final OA	15d	Pending	May 13, 2021
17313369	Biological Fluid Filtration System	Astrin Biosciences, Inc.	LYLE, SOPHIA YUAN	1796	Other	Final Rejection	67d overdue	Pending	May 06, 2021
17313421	Biological Fluid Filtration System	Astrin Biosciences, Inc.	LYLE, SOPHIA YUAN	1796	§103	Non-Final OA	30d overdue	Pending	May 06, 2021
17289602	FORMULATIONS OF MULTISPECIFIC ANTIBODIES BINDING PD-L1 AND CD137	BIONTECH SE	KIM, YUNSOO	1641	Other	Non-Final OA	49d overdue	Pending	Apr 28, 2021
17235153	OLIGONUCLEOTIDES FOR MSH3 MODULATION	UNIVERSITY OF MASSACHUSETTS	VYAS, KEYUR ANILKUMAR	1637	§103	Final Rejection	5d	Pending	Apr 20, 2021
17162450	Biological Fluid Filtration System	Astrin Biosciences, Inc.	LYLE, SOPHIA YUAN	1796	§112	Non-Final OA	35d overdue	Pending	Jan 29, 2021
17050462	RADIATION SENSITIVITY ENHANCING COMPOSITION CONTAINING ARIPIPRAZOLE AS ACTIVE INGREDIENT	Korea Institute Of Radiological & Medical Sciences	THOMAS, TIMOTHY P	1614	Other	Final Rejection	99d overdue	Pending	Oct 26, 2020
16998587	TARGETED FLUORESCENT MARKERS IN COMBINATION WITH A FLEXIBLE PROBE	On Target Laboratories, LLC	SCHLIENTZ, LEAH H	1618	§103	Final Rejection	162d overdue	Pending	Aug 20, 2020
15555811	MICROPARTICLES	Spheritech Ltd.	LOVE, TREVOR M	1611	Other	Final Rejection	11d overdue	Pending	Sep 05, 2017
14112731	CROSS-LINKED POLY-E-LYSINE PARTICLES	Spheritech Ltd.	MOSS, NATALIE M	1653	§103	Final Rejection	29d	Pending	Jan 23, 2014

Show all 95 rows (45 more)

Managing Lathrop Gpm LLP's Patent Prosecution?

IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial